GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence SUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain taking place Oct. 23-27, 2026.
Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.
Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) rose 5.5% during mid-day trading on Wednesday. The stock traded as high as $141.97 and last traded at $144.0280. Approximately 113,792 shares were traded during trading, a decline of 88% from the average daily volume of 962,223 shares. The stock had previously closed at $136.57. Analyst
Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) hit a new 52-week high on Thursday. The company traded as high as $151.46 and last traded at $140.12, with a volume of 1920136 shares trading hands. The stock had previously closed at $136.57. Wall Street Analysts Forecast Growth Several equities research analysts recently issued reports
Grail's stock recently hit its all-time high. If the FDA approves Galleri, it still looks reasonably valued.
The key to the company's future is medical insurers adopting Galleri. The FDA looks likely to grant pre-market approval for Galleri following this week's vote.
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CFO Aaron Freidin sold 4,100 shares of the company's stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $93.34, for a total transaction of $382,694.00. Following the transaction, the chief financial officer owned 248,983 shares in the company,
Grail's stock surged 55% after a favorable FDA committee vote, and ultimately, FDA approval could drive insurer adoption and broader market access. Galleri's efficacy vote was close, reflecting ongoing concerns about effectiveness.
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 61,452 shares of the firm's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the sale, the chief executive officer owned 362,271 shares of the company's stock, valued
There are many unrecognized trade-offs to home ownership that can make renting a better economic choice.
